| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate |
2006-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2009-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2009515979-A |
| titleOfInvention |
Methods for treating joint damage |
| abstract |
Treatment-eligible comprising administering to the subject an antagonist (eg, a CD20 antibody) that binds to a B cell surface marker in an amount effective to delay the progression of joint damage as determined by radiography. A method of treating joint damage in a subject is provided. Further useful products for such methods are provided. In a first aspect, the invention relates to a method for treating joint damage in a subject comprising administering to the subject a CD20 antibody and prior to administration at least about 1 month after administration. Providing the subject with an x-ray examination to determine a reduction in joint damage as compared to baseline, wherein the amount of CD20 antibody administered is effective to achieve the reduction in joint damage It is a quantity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10618973-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10918714-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10538592-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017517518-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11319567-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11332523-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11267870-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11377485-B2 |
| priorityDate |
2005-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |